AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.310
+0.010 (0.43%)
Jul 28, 2026, 11:44 AM EDT - Market open

AC Immune Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
229319271496171413
Market Cap Growth
-6.08%17.84%-45.35%190.80%-58.72%11.11%
Enterprise Value
140.2821093.91377.6841.02199
Last Close Price
2.313.142.705.002.044.95

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-14.2114.2166.3866.3866.38
PS Ratio
49.4470.958.9728.1940.08-
PB Ratio
5.775.652.182.600.931.62
P/TBV Ratio
--4.353.841.442.04
P/FCF Ratio
--3.75---
P/OCF Ratio
--3.72---

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
30.3946.643.1121.469.64-
EV/FCF Ratio
--1.30---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.110.080.040.020.010.01
Debt / FCF Ratio
--0.08---
Net Debt / Equity Ratio
-2.23-1.93-1.43-0.62-0.71-0.84
Net Debt / EBITDA Ratio
1.091.303.171.831.682.47
Net Debt / FCF Ratio
-1.24-2.451.631.602.86
Asset Turnover
0.030.020.130.080.020
Quick Ratio
0.830.981.668.7410.759.97
Current Ratio
0.871.021.719.2211.1610.12
Return on Equity (ROE)
-173.31%-89.65%-37.31%-32.91%-35.29%-32.63%
Return on Assets (ROA)
-44.23%-36.09%-25.46%-30.70%-32.88%-32.54%
Return on Invested Capital (ROIC)
---791.96%-102.64%-171.28%-571.45%
Return on Capital Employed (ROCE)
-123.18%-73.31%-35.19%-32.93%-35.36%-34.91%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
FCF Yield
--26.65%---
Buyback Yield / Dilution
-0.43%-1.06%-17.71%-1.36%-11.48%-4.24%
Total Shareholder Return
-0.43%-1.06%-17.71%-1.36%-11.48%-4.24%
SEC Filings: 10-K · 10-Q